Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VISUDYNE
- Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
- Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
- Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
- Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System
- Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
- An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
- Treatment of Primary Breast Cancer Using PDT
- Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
- Photodynamic Therapy for the Treatment of Vertebral Metastases
- Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
- Aflibercept in Polypoidal Choroidal Vasculopathy
- Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization
- ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study
- Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
- Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
- VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
- Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
- Ranibizumab for Myopic Neovascularization
- Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
- Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
- Lucentis to Treat Pigment Epithelial Detachment
- Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
- Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
- Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)
- Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-Related Macular Degeneration
- Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
- Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
- The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
- Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
- Photodynamic and Pharmacologic Treatment of CNV
- Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis
- Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
- Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
- Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
- Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD
- Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
- Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
- Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
- Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
- Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
- Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
- The Avastin vs Visudyne for Neovascular AMD Study
- Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
- Macugen for Histoplasmosis
- A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
- Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
- Treatment of Age-Related Macular Degeneration With Anecortave Acetate
- Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
- Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
- Visudyne® in Occult (VIO)
- Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
- A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
- Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
- Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
- Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
- Phase II/III Study of Anti-VEGF in Neovascular AMD
Clinical trials list
click for details